These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 8175045

  • 1. Comparison of in vitro and in vivo properties of rhirudin (HBW 023) and a synthetic analogous peptide.
    Römisch J, Diehl KH, Hoffmann D, Krahl-Mateblowski U, Reers M, Stüber W, Pâques EP.
    Haemostasis; 1993; 23(5):249-58. PubMed ID: 8175045
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin.
    Jakubowski JA, Maraganore JM.
    Blood; 1990 Jan 15; 75(2):399-406. PubMed ID: 2294999
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
    Komatsu Y, Inoue Y, Goto Y, Fukazawa T, Hayashi H.
    Thromb Haemost; 1999 Feb 15; 81(2):250-5. PubMed ID: 10064001
    [Abstract] [Full Text] [Related]

  • 4. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct 15; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide.
    Römisch J, Stöhr HA, Stauss H, Koschinsky R, Stüber W, Pâques EP.
    Thromb Haemost; 1994 Mar 15; 71(3):320-4. PubMed ID: 8029796
    [Abstract] [Full Text] [Related]

  • 6. Antithrombin effects of native and recombinant hirudins.
    Markwardt F, Stürzebecher J, Glusa E.
    Biomed Biochim Acta; 1990 Mar 15; 49(5):399-404. PubMed ID: 2271010
    [Abstract] [Full Text] [Related]

  • 7. Hirudisins. Hirudin-derived thrombin inhibitors with disintegrin activity.
    Knapp A, Degenhardt T, Dodt J.
    J Biol Chem; 1992 Dec 05; 267(34):24230-4. PubMed ID: 1447173
    [Abstract] [Full Text] [Related]

  • 8. Hirudin C-terminal fragments inhibit thrombin induced neutrophil chemotaxis.
    Rowand JK, Marucha P, Berliner LJ.
    Thromb Haemost; 1992 Mar 02; 67(3):289-91. PubMed ID: 1641817
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of a multifunctional staphylokinase variant with thrombin inhibition and antiplatelet aggregation activities produced from salt-inducible E. coli GJ1158.
    Kumar A, Pulicherla KK, Mayuren C, Kotra S, Rao KR.
    Can J Physiol Pharmacol; 2013 Oct 02; 91(10):839-47. PubMed ID: 24144055
    [Abstract] [Full Text] [Related]

  • 10. Anticoagulant activity of synthetic hirudin peptides.
    Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL.
    J Biol Chem; 1989 May 25; 264(15):8692-8. PubMed ID: 2722794
    [Abstract] [Full Text] [Related]

  • 11. The effects of recombinant desulphatohirudin on arterial thrombosis in rats.
    Talbot MD, Ambler J, Butler KD, Lees CM, Mitchell KA, Peters RF, Tweed MF, Wallis RB.
    Haemostasis; 1991 May 25; 21 Suppl 1():73-9. PubMed ID: 1654294
    [Abstract] [Full Text] [Related]

  • 12. Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptides.
    Church FC, Phillips JE, Woods JL.
    J Biol Chem; 1991 Jun 25; 266(18):11975-9. PubMed ID: 2050691
    [Abstract] [Full Text] [Related]

  • 13. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM, Hoppensteadt D, Koza M, Wallock M, Pifarre R, Fareed J.
    Haemostasis; 1991 Jun 25; 21 Suppl 1():49-63. PubMed ID: 1894197
    [Abstract] [Full Text] [Related]

  • 14. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC, Dieter JP, Strebel LC, Taylor TM, Muscolino G, Feinberg H, Le Breton GC.
    J Pharmacol Exp Ther; 1991 Dec 25; 259(3):1371-8. PubMed ID: 1762085
    [Abstract] [Full Text] [Related]

  • 15. Biology of recombinant hirudin (CGP 39393): a new prospect in the treatment of thrombosis.
    Talbot M.
    Semin Thromb Hemost; 1989 Jul 25; 15(3):293-301. PubMed ID: 2688102
    [No Abstract] [Full Text] [Related]

  • 16. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
    Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA.
    Proc Natl Acad Sci U S A; 1992 Jul 01; 89(13):6040-4. PubMed ID: 1385867
    [Abstract] [Full Text] [Related]

  • 17. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
    Elg M, Gustafsson D, Deinum J.
    Thromb Haemost; 1997 Oct 01; 78(4):1286-92. PubMed ID: 9364999
    [Abstract] [Full Text] [Related]

  • 18. Recombinant leech antiplatelet protein prevents collagen-mediated platelet aggregation but not collagen graft thrombosis in baboons.
    Schaffer LW, Davidson JT, Siegl PK, Gould RJ, Nutt RF, Brady SF, Connolly TM.
    Arterioscler Thromb; 1993 Nov 01; 13(11):1593-601. PubMed ID: 8218100
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition.
    Mo W, Zhang YL, Chen HS, Wang LS, Song HY.
    J Thromb Thrombolysis; 2009 Aug 01; 28(2):230-7. PubMed ID: 18998199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.